Castration-resistant prostate cancer at high risk of metastasis: enzalutamide has added benefit

(Institute for Quality and Efficiency in Health Care) Castration-resistant prostate cancer at high risk of metastasis: enzalutamide has added benefit. For the first time, new data from the PROSPER study show an advantage in overall survival that outweighs the disadvantages in some side effects.